Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy

Table 3 Results of uni- and multivariate analyses for biochemical progression-free survival (bRFS)

	Univariate analysis	Multivariable analysis
	p value	p value	OR, (95% CI)
Initial T stage (≤T2 vs ≥ T3)	0.02	0.50	1.43 (0.50–4.11)
Initial N stage (N0 vs N1)	0.07	0.07	3.75 (0.89–15.81)
Initial PSA level in ng/ml (≤20 vs > 20)	0.36
PSA nadir after RP (≤0.07 ng/mL vs > 0,07 ng/mL)	0.04	0.14	2.24 (0.78–6.45)
Number of removed LN at RP (≤15 vs > 15)	0.32
Initial Risk Group (intermediate+high risk vs. very high risk)	0.15
PSA doubling time (≤6 months, > 6 months)	0.46
Radiotherapy type (CF-RT vs. SBRT)	0.11
No. of irradiated metastases (1 vs > 1)	0.37
Type of metastases (lymph node vs bone)	0.18
Concurrent ADT (yes vs no)	0.03	0.01	7.86 (1.51–40.79)
RT-Dose (≤50 Gy vs > 50 Gy)	0.74

ADT androgen deprivation therapy, CF-RT conventionally fractionated radiotherapy type, dt doubling time, Gy Gray, LN lymph nodes, PSA prostate-specific antigen, RP radical prostatectomy, sRT salvage radiotherapy, SBRT stereotactic body radiation therapy, SIB simultaneous integrated boost

ISSN: 1471-2407